Abstract. Lipid bodies, nonmembrane-bound cytoplasmic inclusions, serve as repositories of esterified arachidonate and are increased in cells associated with inflammatory reactions. We have evaluated stimuli and mechanisms responsible for lipid body formation within human polymorphonuclear leukocytes (PMNs). Arachidonic acid and oleic acid stimulated dosedependent formation of lipid bodies over 0.5-1 h. Other C20 and C18 fatty acids were less active and demonstrated rank orders as follows: cis-unsaturated fatty acids were much more active than trans-fatty acids, and activity diminished with decreasing numbers of double bonds. Lipid bodies elicited in vitro with cis-fatty acids were ultrastructurally identical to lipid bodies present in PMNs in vivo. Lipid body induction was not because of fatty acid-elicited oxidants or fatty acid-induced ATP depletion. Cis-fatty acidinduced activation of protein kinase C (PKC) was involved in lipid body formation as evidenced by the capacity of other PKC activators, 1-oleoyl-2-acetylglycerol and two active phorbol esters, phorbol myristate acetate, and phorbol 12,13 dibutyrate, but not an inactive phorbol, to induce lipid body formation. The PKC inhibitor, 1-O-hexadecyl-2-O-methylglycerol, inhibited PMN lipid body formation induced by oleic and arachidonic acids and by 1-oleoyl-2-acetylglycerol and phorbol myristate acetate. Other PKC inhibitors (staurosporine, H-7) also inhibited lipid body formation. Formation of lipid bodies in PMNs is a specific cellular response, stimulated by cis-fatty acids and diglycerides and apparently mediated by PKC, which results in the mobilization and deposition of lipids within discrete, ultrastructuraUy defined cytoplasmic domains. zPID bodies are nonmembrane bound, cytoplasmic inclusions present within neutrophilic (49) and eosinophilic (48) leukocytes, fibroblasts (52), endothelial cells (23), and other cell types (23). The genesis and functions of lipid bodies are largely unknown in most cells. In both neutrophils (polymorphonuclear leukocytes; PMNs) L (49) and eosinophils (48), lipid bodies become more prominent in number and size when these leukocytes are engaged in inflammatory responses. Increased numbers of lipid bodies in human PMNs associated with various infectious, neoplastic, and other inflammatory reactions have been demonstrated both within biopsied tissues and in PMNs from blood and exudative effusions (13, 49). In addition, PMNs from experimentaUy elicited peritoneal exudates in rabbits, but not PMNs collected concurrently from rabbit peripheral blood, contained increased numbers of lipid bodies (36). These in vivo findings with human and rabbit PMNs indicated that 1. Abbreviations used in this paper: BHT, butylated hydroxytoluene; fMLE N-formyl-methionyl-leucyl-phenylalanine; HMG, 1-O-hexadecyl-2-O-methylrac-glyeerol; PDBu, phorbol 12,13 dibutyrate; PDD, 40t-phorbol 12,13 dideeanoate; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; PMNs, polymorphonuclear leukocytes (neutrophils); OAG, 1-oleoyl-2-acetyl-rac-glycerol; 2,4 DNP, 2,4 dinitrophenol. lipid body formation was a morphologic correlate of the cells' participation in inflammation. It is PMNs in sites of inflammation, not normal blood PMNs, that are likely to be subjected to activating cellular ligands and lipids and to be engaged in stimulated cellular responses, including eicosanoid synthesis and release. Whether lipid body formation represents a toxic sequela or a specific response within PMNs has not been defined; and mechanisms responsible for lipid body formation in leukocytes or other cell types have not been identified (36).
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Although the composition and functions of lipid bodies in leukocytes remain uncertain, a role for lipid bodies as major intracellular sites of deposition of fatty acids, including arachidonic acid, has been indicated by electron microscopic autoradiography (18, 19, 23, 48, 49) . In human PMNs (49) and eosinophils (48) , lipid bodies were the predominant sites of localization of cell-incorporated, esterified [3H]-arachidonate (49) . Other pH]-fatty acids also localized to PMN lipid bodies (49) . Similarly, incorporation of [3H]-arachidonate into lipid bodies of human alveolar macrophages and mast cells (18, 19) and murine and guinea pig peritoneal macrophages (18) has been demonstrated.
Since lipid bodies in leukocytes can serve as stores of esterified arachidonate and increase in number when these cells are involved in inflammatory responses, we have investigated stimuli and mechanisms which lead to lipid body formation in PMNs. We have found that induction of lipid body formation is mediated by activation of protein kinase C (PKC) and can be elicited preferentially by cis-unsaturated fatty acids, which can activate PKC (15, 29, 30) , and by other PKC activators, 1-oleoyl-2-acetyl-rac-glycerol (OAG) and specific phorbol esters (10, 22, 32) . PKC activation in PMNs elicits multiple alterations in lipid metabolism, including increases in classes ofdiglycerides (1, 16, 35, 47) and phospholipids (28, 41, 46) and priming for stimulated release of eicosanoids (27, 28) . In the context of these PKC-mediated biochemical changes in lipids, PKC activation also promotes the mobilization and deposition of lipids into discrete cytoplasmic inclusions. In combination with observations that lipid bodies are a potential intracellular source of esterified arachidonate, these findings suggest that lipid bodies in PMNs may have a role in eicosanoid production by these cells. 
Materials and Methods

Materials
PMN Purification and Lipid Body Induction
Peripheral blood from normal donors was anticoagulated with acidified citrate; erythrocytes were removed by dextran sedimentation; and granulocytes (>95 % PMNs, remainder eosinophils) were collected after centrifugation on Ficoll-Hypaque (49) and washed in calcium, magnesium-free HBSS. Residual erythrecytes were lysed with hypotohic saline, and PMNs were resuspended in calcium, magnesium-free Tyrode's buffer (0.1% wt/vol) dextrose, 0.1% NaHCOs, 0.02% KC1, 0.8% NaC1, 0.005% NaH2POa, pH 7.5) with 0.1% gelatin. Incubations were done with gelatin and not albumin to minimize protein binding of fatty acids and were done without exogenous calcium to avoid effects of calcium on the solubility or membrane partitioning of fatty acids (45) . In representative experiments, cell viability was checked with trypan blue staining, and for each of the fatty acids was >90%. PMNs (10~/ml in 3 ml) were incubated at 37°C for 60 rain, a time which yielded near maximal lipid body formation for both arachidonic and oleic (49) acids. To minimize toxicity to cells, incubations with PMA or with inhibitors of PKC were limited to 30 min; and with PKC inhibitors, stimulating fatty acids and OAG were used at submaximal (2.5 #M) concentrations. Possible cytotoxicity was also assessed by evaluating morphology of fixed PMNs during lipid body counting. Fatty acids, diacylglycerides, and lysophosphatidylcholine, dissolved in ethanol, were used at a final 0.1% ethanol concentration. Control cells were incubated likewise in 0.1% ethanol. Within all experiments, incubations with 1 or 2.5 #M oleic acid were included as positive control conditions for PMN lipid body formation. Phorbol esters, HMG, valinomycin, and staurosporine were dissolved in dimethylsulfoxide; control cells were incubated in 0.1% dimethylsulfoxide. H-7 was dissolved as a stock solution in distilled water. HMG, staurosporine, and H-7 were added ptewarmed at 370C to 37°C prewarmed PMNs for 15 rain before adding fatty acids or other stimuli. Superoxide dismutase and catalase solutions were heat inactivated for 15 rain in boiling water.
Lipid Body Staining and Enumeration
PMNs ('~5 × 104) were cytocentrifuged (Cytocentfifuge, Shandon, Pittsburgh, PA) (1,000 RPM, 5 rain) onto glass slides. In early studies, slides, while still moist, were fixed by exposure to OsO4 vapors, and then stained for 2-4 h in oil red O (6 parts 0.5% [wt/vol] oil red O in isopropanol, 4 parts water), rinsed briefly in isopropanol, and then mounted with Apathy's medium. In later studies, greater contrast of lipid bodies was obtained by staining slides sequentially with ferrocyanide-reduced OsO4, thiocarbohydrazide and OsO4 (53) . Slides were fixed in 3.0% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4 (15 rain), rinsed twice in cacodylate buffer (3 rain), stained in 1.5% K4Fe(CN)6 in 1.0% aqueous OsO4 (30 min), rinsed three times in water, immersed in 1.0% thiocarbohydrazide (5 min), rinsed three times in water, restained in 1.0% OsO4 in 0.1 M cacodylate (3 min), rinsed with water, and then dried and mounted in Apathy's medium. The morphology of fixed cells was observed, and lipid bodies were enumerated with phase contrast microscopy, and a 100× objective lens in 25-50 consecutively scanned PMNs; any eosinophils were not counted. Results were calculated as mean (+SEM) lipid bodiesdPMN or as mean net (:I:SEM) lipid bodies/PMN, after subtracting the lipid bodies/PMN formed during control incubations.
EM of PMN Lipid Bodies
Ceils for EM were processed and examined as previously detailed (17, 49) . PMNs were fixed in 2% paraformaldehyde, 2.5% ghitaraldehyde, 0.025% CaC12 in 0.1 M sodium cacodylate buffer, pH 7.4 for 1 h, washed in cold 0.1 M cacodylate buffer, and rapidly centrifuged through molten agar. The cell pellets in agar were postfixed in S-collidine-buffered osmium and stained en bloc with uranyl acetate before dehydration in a graded series of alcohols and embedding in a propylene oxide-Epon sequence. Thin sections were stained with lead citrate and examined in an electron microscope (Model 400; Philips Electronic Instruments, Inc., Mahwah, NJ).
PKC Assays
PKC activity in cytosolic fractions of PMNs was assayed by quantitating phosphorylation of a synthetic PKC substrate peptide (PKC assay system; Amersham Corp., Arlington Heights, IL). After hypotonic erythrocyte lysis, PMNs, purified as described above, were washed with HBSS and resuspended at 5 x 107/ml in 50 mM Tris-HC1, pH 7.5, 2 mM EGTA, 50 mM 2-mercaptoethanol, and 1 mM phenylmethylsulfonyl fluoride. PMNs were disrupted using an ice-cold homogenizer with multiple passes to achieve ,x,75 % cell breakage; and cytosol was recovered after centrifugation (150,000 g for 90 mins, 4°C). Assays were performed as specified by the manufacturer except that phosphatidylserine and diolein were substituted for the supplied lipid mixture. The standard assay mixture contained 25 #1 cytosolic fractions, 2 #1 without or with either HMG (in varying concentrations), 50/zM H-7 or 50 #M stanrosporine, 2 #1 2 #g/ml diolein, and 25 tA 12 mM calcium acetate, 30 mM dithiothreitol, 900 #M PKC substrate peptide in 50 mM Tris-HCl, pH 7.5, with 0.05 % sodium azide and 20 #g/ml phosphatidylserine. Reactions were started by adding 25 #1 of magnesium ATP buffer (150 #M ATP, 45 mM magnesium acetate, 10 #Ci/ml s2p_),_ ATP (3,000 Ci/mmol, Amersham Corp.), in 50 mM Tris-HC1, pH 7.5), incubated for 15 min at 25"C, and then stopped with acidic reaction-quenching reagent. Phosphorylated substrate was trapped on peptide-binding paper, washed with acetic acid, and counted by liquid scintillation spectrometry. Assays were done within conditions of linearity for time and protein. In repeated experiments measured PKC activity was >94% calcium and phospholipid dependent (assessed in 12 rnM EGTA without added diolein, phosphatidylserine, and calcium) and ranged •0.15 nmol phosphate incorporated/rain/rag protein. Results are derived from means of triplicate or quadruplicate assays for each condition. (49), we investigated lipid body formation in PMNs incubated with fatty acids of varying structures. Arachidonic and oleic acids were about equipotent in eliciting dose-dependent increases in lipid body formation, but the methyl esters of these fatty acids and arachidonyl alcohol were ineffective (Fig. 2) . The morphology of lipid bodies elicited in vitro in PMNs incubated with these fatty acids was ultrastructurally identical (Fig. 3) , including size range, consistency and electron density after osmium fixation, to native lipid bodies formed in vivo in blood and tissue PMNs (49) . In addition, lipid bodies in PMNs exposed to oleic and arachidonic acids had an identical investiture, not with a defined unit membrane, but with an electron dense, peripheral lipid body "shell" partially or fully around their circumference (Fig. 3 B) , as also found on PMN lipid bodies in vivo (49) .
Induction of lipid body formation by other fatty acids with different degrees of unsaturation and double-bond geometries was examined. With 20 carbon fatty acids (Fig. 4 A) , potency for lipid body induction increased progressively with the number of cis double bonds in the fatty acid. At 10 #M fatty acid, the rank order for lipid body induction was arachidonic acid (eicosatetraenoic acid, C20:4, cis 5,8,11, 14) -homo-3,-linoleic acid (eicosatrienoic acid, C20:3, cis 40 40' A B 8,11,14) > eicosadienoic acid (C20:2, cis 11,14) > eicosenoic acid (C20:1, cis 11) > eicosadienoic acid (C20:2, trans 11, 14) > eicosenoic acid (C20:1, trans 11) > eicosanoic acid (C20:0). The rank order with increasing degrees of unsaturation was also evident with 18 carbon fatty acids (Fig. 4 B) , as was the importance of the geometry of double bonds. With 10 #M fatty acid, potency for lipid body induction was oleic acid (C18:1, cis 9) > ~,-linoleic acid (C18:3, cis 6,9,12) > linoleic acid C18:2, cis 9,12) > linoleidic acid (C18:2, trans 9,12) > elaidic acid (C18:1, trans 9) > stearic acid (C18:0). Effects of unsaturated fatty acids were additive. Whereas PMNs incubated alone with 1 #M oleic acid or 1 or 2.5 #M Figure 4 . Induction of PMN lipid body formation by C20 fatty acids (A) and C18 fatty acids (B). C20 fatty acids included arachidonic acid (eicosatetraenoic acid, C20:4, cis 5, 8, 11, 14) , homo-3,-linoleic acid (eicosatrienoic acid, C20:3, cis 8, 11, 14) , eicosadienoic acid (C20:2, cis 11, 14), eicosenoic acid (C20:1, cis 11), eicosadienoic acid (C20:2, trans 11,14), eicosenoic acid (C20:1, trans 11), and eicosanoic acid (C20:0). C18 fatty acids included oleic acid (C18:1, cis 9), y-linoleic acid (C18:3, cis 6, 9,12), linoleic acid (C18:2, cis 9,12), linoleidic acid (C18:2, trans 9,12), elaidic acid (C18:1, trans 9), and stearic acid (C18:0). Mean lipid bodies/PMN in 25-50 cells were corrected for lipid bodies (between 1-4/PMN) in PMNs incubated with control 0.1% ethanol. Results are means from six experiments with arachidonic acid, from two each with 11,14 trans-eicosadienoic, 11 transeicosenoic, and eicosanoic acids, from eight with oleic acid and three with linoleic acid. arachidonic acid contained I0.4 + 3.2 (+SEM), 9.9 + 3.5 and 17.3 + 4.3 lipid bodies/PMN, respectively, combinations of 1/~M oleic acid with 1 or 2.5/~M arachidonic acid yielded 16.6 + 4.8 and 27.7 + 7.0 lipid bodies/PMN. In contrast to cis-unsaturated fatty acids, the fully saturated fatty acids, palmitic (C16:0) and myristic (C14:0), two diglycerides, dipalmitin and diolein, and lysophosphatidylcholine, at concentrations up to 10/~M, failed to induce lipid body formation (data not shown).
Mechanism of Lipid Body lnducaon
Since lipid body formation was not elicited simply by exposures to exogenous lipids but was structurally dependent on the composition and stereochemistry of stimulating fatty acids, potential mechanisms of lipid body formation were sought from the recognized effects of fatty acids, especially cis-unsaturated fatty acids, on PMNs.
Potential Toxic Effects of cis-Fatty Acids. Focal cytoplasmic accumulations of lipids might have developed as adverse consequences of fatty acid-stimulated metabolic events in PMNs. Specific fatty acids, notably cis-unsaturated fatty acids, stimulate the respiratory burst of PMNs (4, 5) , and the potencies of various polyunsaturated fatty acids as stimuli for PMN superoxide anion release (4, 5) were approximately the same for lipid body induction. To evaluate whether fatty acid-elicited superoxide anion or H20~ contributed to lipid body formation, superoxide dismutase and catalase were added during incubations of PMNs with oleic acid. These enzymes, in amounts sufficient to consume superoxide anion or H202 released by stimulated PMNs, did not inhibit oleic acid-induced lipid body formation but rather augmented lipid body formation (Fig. 5 A) . In the presence of active, but not heat inactivated, superoxide dismutase plus catalase, oleic acid-stimulated lipid body numbers were greater than without these enzymes. In addition, the antioxidant, BHT, did not inhibit, but also significantly enhanced, oleic acid-induced lipid body formation (Fig. 5 B) .
Oxidant stress of cells evoked by exposures to H202, superoxide anion or PMA-stimulated PMNs can deplete cellular ATP (44) , and cis-fatty acids can uncouple mitochondrial oxidative phosphorylation (3, 38) . cis-Unsaturated, but not saturated, fatty acids have depleted cellular ATP and conse- not promote oleic (or palmitic) acid-mediated lipid body formation, but instead significantly (p < 0.0001, t test) inhibited oleic acid-induced lipid body formation (Table I) .
cis-Fatty Acids and PKC Activation.
Because fatty acids, especially cis-fatty acids, can activate PKC, other stimuli of PKC were evaluated. In contrast to the ineffectiveness of dipalmitin and diolein, the cell permeable, PKC-activating diglyceride, OAG, was a potent stimulator of lipid body formation (Figs. 1 B and 6 A) . The PKC-activating phorbol ester, PMA, induced PMN lipid body formation within 30 min with maximal lipid body formation at 20 nM (Fig. 6 B) . Another phorbol ester, PDBu, at 2 and 20 nM, also elicited lipid body formation, with about 1/6th the molar potency of PMA; whereas PDD, a phorbol not activating PKC, elicited no induction of lipid bodies in concentrations up to 200 nM (data not shown). In the presence of superoxide dismutase plus catalase, greater numbers of lipid bodies were formed in response to PMA (Fig. 6 B) and PDBu, but not PDD (data not shown), as well as to OAG, arachidonic acid (data not shown), and oleic acid (Fig. 5 A) .
PKC Inhibition and Fatty Acid-induced Lipid Body Formation.
To further evaluate the role of PKC activation, the effects of several PKC inhibitors on fatty acid-induced lipid body formation were assessed. HMG, an effective inhibitor of PKC-mediated processes in human PMNs (25) , potently inhibited lipid body formation induced by 2.5 #M concentrations of oleic acid, arachidonic acid, and OAG, 20 nM PMA (Fig. 7) and 20 nM PDBu (data not shown). HMG, at only 3/~M, produced about 50 % inhibition of lipid body formation induced by each of these stimuli. HMG, in the concentrations used, inhibited cytosolic PKC activity of disrupted PMNs (Fig. 7 C) . Other PKC inhibitors were also tested. With 1/~M staurosporine, lipid body formation induced by 2.5/~M arachidonic acid, oleic acid, and OAG was inhibited (mean + SEM, n --3) 39 + 21%, 48 + 10%, and 23 5: 1%, respectively; and with 40 #M H-7 and the same three stimuli, mean inhibition (n = 2) was 52 + 18%, 91 + 7%, and 92 + 8%, respectively. H-7 at 25 and 50 #M and staurosporine at 50 #M inhibited PKC activity 24, 77, and 83 %, respectively, when assayed on disrupted PMNs. Sphingosine (5-25/~M) could not be evaluated since it was toxic to PMNs, in accord with previous findings (26) , under conditions used for lipid body induction (e.g., 30-45 min with exogenous fatty acids but no BSA). The inhibition of cis-fatty acid-and diglyceride-stimulated lipid body induction by staurosporine and H-7 supported the findings with HMG indicating that lipid body formation was mediated by PKC activation.
Discussion
Although lipid bodies occur in a wide variety of cell types, mechanisms of formation and functions of these lipid-rich cytoplasmic inclusions have been uncertain. Normal blood PMNs have few lipid bodies, ,~0.7 per cell; but tissue, exudate, and blood PMNs, when associated with inflammatory reactions, contain increased lipid body numbers (13, 23, 49) . Lipid bodies serve as nonmembrane stores of esterified arachidonate, as evidenced by autoradiography of PMNs (49), eosinophils (48) , and other cells (18, 19, 23) , and by lipid analyses of lipid bodies isolated from oosinophils (50) . Lipid bodies, ultrastructurally identical to lipid bodies in PMNs in vivo, were elicited in PMNs incubated with arachidonic and oleic acids (Fig. 3) (49) . In evaluating mechanisms of lipid body formation in PMNs, our studies have indicated that activation of PKC, by these fatty acids or other stimuli, is involved in lipid body formation. While incubation of PMNs with exogenous fatty acids provides a source of lipids for incorporation into newly forming lipid bodies, the structurally restricted capacities of different fatty acids and lipids to induce lipid bodies indicated that mechanisms other than simple availability of lipid precursors were involved in lipid body formation. Palmitic acid, like other saturated fatty acids (eicosanoic, stearic, and myristic), failed to elicit lipid body formation; but [3H]-palmitic acid, like pH]-arachidortic and [3H]-oleic acids, is freely taken up by PMNs (34, 49) and incorporated into PMN lipid bodies (49) . Thus, while some lipids evaluated, including the diglycerides, dipalmitin and diolein, and the fatty acid methyl esters, are minimally permeant to intact cells, inability to be incorporated into cells or lipid bodies would not account for the failure of saturated fatty acids to elicit lipid body induction, nor would differential incorporation explain the compositionally and stereochemically dependent lipid body-inducing activities of various unsaturated fatty acids (Fig. 4) .
The preferential lipid body-inducing activities of cis-unsaturated fatty acids were not attributable to sequelae associated with other metabolic effects of these fatty acids. In cells with active oxidative phosphorylation, including macrophages (33) and lymphocytes (3), cis-unsaturated fatty acids can uncouple oxidative phosphorylation and cause ATP depletion, which might impair fatty acid esterification (11). In PMNs three inhibitors of oxidative phosphorylation did not elicit lipid body formation and did not augment fatty acid-induced lipid body formation to levels attainable with greater fatty acid concentrations. Moreover, PMNs, in contrast to other leukocytes, derive only 0.01-0.1% of their ATP from oxidative phosphorylation (24) , so inhibition of oxidative phosphorylation would not account for cis-fatty acid elicitation of PMN lipid bodies. Inhibition of glycolytic ATP generation also did not promote, but rather significantly inhibited, fatty acid-induced lipid body formation (which was also inhibited at 4°C, data not shown). The lack of inhibition of oleic acid-induced lipid body formation by BHT helped exclude roles for free radical species, products of lipid peroxidation derived from unsaturated fatty acids (20) , or oxidant-induced ATP depletion (44) in the genesis of lipid bodies. Analogously, since superoxide dismutase plus catalase did not inhibit stimulated lipid body formation, but rather augmented it (as considered more fully below), respiratory burst products released extracellularly from cis-fatty acid-stimulated PMNs (4, 5) were not involved in promoting lipid body formation. Thus, lipid body formation was temperature and energy dependent but not due to cis-fatty acid-induced ATP depletion or cis-fatty acid-elicited oxidants.
Instead, the lipid body-inducing activities of cis-fatty acids could be accounted for by their capacities to stimulate PKC (15, 30, 39, 40, 42) , including human PMN PKC (29, 43) . Since PKC species, including those in human PMNs (29) , can be activated by cis-unsaturated fatty acids and not by trans-or saturated fatty acids, such activation would explain the preferential activities of cis-unsaturated fatty acids as inducers of lipid body formation. In support of this mechanism, lipid body formation was stimulated by other PKC activators, OAG, a cell permeable diglyceride well recognized to activate PKC (22, 32) , PMA, and PDBu, both phorbol ester activators of PKC (10), but not PDD, a phorbol without activity for PKC (10 (48, 49, 50) . Lipids forming these inclusions are not derived solely from exogenous fatty acids or diglycerides, however, since phorbol esters can induce lipid body formation. Phorbol ester stimulation of PMNs has increased fatty acid incorporation into phospholipids (46) , promoted accumulation of phospholipid classes (41) , and stimulated increases in 1,2 diacyl-and 1-O-alkyl-2-acyl-glycerols (1, 16, 35, 47) . Some of these endogenously formed lipids may be mobilized for inclusion within developing cytoplasmic lipid bodies. The augmentation of lipid body formation by superoxide dismutase and catalase was notable, since all inducers of lipid body formation studied (arachidonic, oleic, and other cis-fatty acids, OAG, and PMA) can elicit a respiratory burst in PMNs (4, 5, 22) • The diminished fatty acid-, but not phorbol ester-, stimulated lipid body induction by heat-inactivated superoxide dismutase and catalase was probably because of protein binding of fatty acids by the quantifies of enzymes used. The enhancing effects both of active, extracellular superoxide dismutase plus catalase (despite protein binding of fatty acid stimuli) and of BHT suggest that respiratory burstderived oxidative products inhibit lipid body formation. Extracellular oxidants might diminish stimulating fatty acid concentrations by oxidative alterations of the cis-fatty acids (21) , although it is unclear if oxidants would similarly degrade OAG and PMA. Alternatively, oxidative products might act intracellularly to inhibit lipid body formation, as suggested by the findings with BHT-treated PMNs that were washed to remove free BHT. Whatever the mechanism, superoxide anion, H202, or derivative compounds (e.g., HOCI, chloramines) appear to inhibit lipid body formation in PMNs.
Conditions for inducing lipid body formation (i.e., 30-60-rain time course and specific diglyceride and cis-fatty acid stimuli) are similar to conditions used in studies of PMNs exposed to "priming" stimuli (6, 7, 8 
